US Physical Therapy Inc (USPH) Q4 2025 Earnings Call Transcript

Why It Matters

The new CPT codes remove a major reimbursement barrier, enabling scalable growth and reducing customer‑concentration risk, which could shift Sensus toward sustainable profitability.

Key Takeaways

• Revenue fell to $4.9M, down from $31M.
• New CPT codes enable clear reimbursement for skin cancer.
• Sales shift to smaller practices, reducing concentration risk.
• Inventory rose to $14.6M, backing anticipated demand.
• International shipments grow, notably in China, improving margins.

Pulse Analysis

The introduction of dedicated CPT codes for superficial radiation therapy (SRT) and image‑guided SRT (IGSRT) marks a watershed moment for Sensus Healthcare. By securing unambiguous reimbursement pathways, the company eliminates a longstanding barrier that limited physician adoption of its non‑invasive skin‑cancer solutions. This regulatory win aligns with broader CMS trends favoring outpatient, minimally invasive procedures and positions Sensus to capture a growing share of the non‑melanoma skin‑cancer market, where one in five Americans will face a diagnosis.

Financially, the quarter reflected a painful transition: revenue collapsed to $4.9 million as the firm shed dependence on its historic largest customer. Gross margins slipped to 38.8% amid higher servicing costs tied to the Fair Deal Agreement program, yet operating expenses were trimmed, and cash remains robust at $22.1 million with zero debt. Management’s inventory surge to $14.6 million signals confidence in future demand, while the expanded sales force and targeted trade‑show strategy aim to accelerate lead conversion. The outlook for 2026 hinges on these commercial levers delivering top‑line growth and restoring profitability.

Internationally, Sensus is leveraging MDSAP certification to unlock markets such as Japan and Brazil, while recent shipments to China underscore the margin‑friendly nature of overseas deployments. The company’s focus on smaller and mid‑size practices, combined with flexible acquisition models—ownership, leasing, or Fair Deal Agreements—creates multiple revenue streams and mitigates concentration risk. Investors should monitor the rollout of next‑generation Sentinel 2.0 devices and the pace of CPT‑code‑driven adoption, as these factors will determine whether Sensus can translate regulatory certainty into sustained earnings growth.